Waiting For Pfizer: GSK Will Cut Sales Force Should Pfizer Act First
Executive Summary
GlaxoSmithKline will reduce the size of its sales force and reinvest those expenditures in research and development should Pfizer decide to downsize its sales team, GSK CEO J.P. Garnier said
You may also be interested in...
Avandia Continues To Take Its Toll; GSK Restructuring Will Cut $1.5 Bil., Jobs
Due in part to plummeting Avandia sales, GlaxoSmithKline will cut $1.5 billion in costs through a restructuring program targeting sales and manufacturing, the firm announced in a third quarter sales and earnings call Oct. 24
Avandia Continues To Take Its Toll; GSK Restructuring Will Cut $1.5 Bil., Jobs
Due in part to plummeting Avandia sales, GlaxoSmithKline will cut $1.5 billion in costs through a restructuring program targeting sales and manufacturing, the firm announced in a third quarter sales and earnings call Oct. 24
Quality Not Quantity: Pfizer Cuts Sales Team To Increase Meaningful Contacts
Pfizer's decision to reduce its sales force reflects a change in the company's marketing strategy, but does not mean the firm is facing a shortage of products to support, according to CEO Jeffrey Kindler